UniProt O60218
Aldo-keto reductase family 1 member B10 (O60218)
Aldo-keto reductase family 1 member B10 (UniProt O60218), EC 1.1.1.-: 40 experimental structures and 1 predicted model on GenesisL1, 20 ligands bound, 80 pockets. Binding sites, druggability and experiment against prediction…
- UniProt
- O60218
- Protein
- Aldo-keto reductase family 1 member B10
- EC
- 1.1.1.-
- Experimental structures
- 40
- Predicted models
- 1
- Ligands
- 20
- Pockets
- 80 · 40 records with a druggable one
Structures
41 records of O60218 in the MolNFT archive: 40 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1ZUA | Crystal Structure Of AKR1B10 Complexed With NADP+ And Tolrestat | x-ray diffraction | X | NAP, TOL | 2 (best 0.71) |
| 1ZUA | Crystal structure of AKR1B10 complexed with NADP+ and tolrestat | x-ray diffraction | X | NAP, TOL | 2 (best 0.71) |
| 4GA8 | Human AKR1B10 mutant V301L complexed with NADP+ and sorbinil | x-ray diffraction | A | NAP, SBI | 2 (best 0.71) |
| 4GA8 | Human AKR1B10 mutant V301L complexed with NADP+ and sorbinil | x-ray diffraction | A | NAP, SBI | 2 (best 0.71) |
| 4GAB | Human AKR1B10 mutant V301L complexed with NADP+ and fidarestat | x-ray diffraction | A | NAP, FID, CL | 2 (best 0.71) |
| 4GAB | Human AKR1B10 mutant V301L complexed with NADP+ and fidarestat | x-ray diffraction | A | NAP, FID, CL | 2 (best 0.71) |
| 4GQ0 | Crystal structure of AKR1B10 complexed with NADP+ and Caffeic acid phenethyl ester | x-ray diffraction | A | QAP, NAP | 2 (best 0.74) |
| 4GQ0 | Crystal structure of AKR1B10 complexed with NADP+ and caffeic acid phenethyl ester | x-ray diffraction | A | QAP, NAP | 2 (best 0.74) |
| 4GQG | Crystal structure of AKR1B10 complexed with NADP+ | x-ray diffraction | A | NAP | 2 (best 0.72) |
| 4GQG | Crystal structure of AKR1B10 complexed with NADP+ | x-ray diffraction | A | NAP | 2 (best 0.72) |
| 4I5X | Crystal Structure Of AKR1B10 Complexed With NADP+ And Flufenamic acid | x-ray diffraction | A | FLF, NAP | 1 (best 0.74) |
| 4I5X | Crystal structure of AKR1B10 complexed with NADP+ and flufenamic acid | x-ray diffraction | A | FLF, NAP | 1 (best 0.74) |
| 4ICC | Crystal structure of human AKR1B10 complexed with NADP+ and JF0064 | x-ray diffraction | X | NAP, 64I | 2 (best 0.73) |
| 4ICC | Crystal structure of human AKR1B10 complexed with NADP+ and JF0064 | x-ray diffraction | X | NAP, 64I | 2 (best 0.73) |
| 4JIH | Crystal Structure Of AKR1B10 Complexed With NADP+ And Epalrestat | x-ray diffraction | A | EPR, NAP | 2 (best 0.73) |
| 4JIH | Crystal structure of AKR1B10 complexed with NADP+ and epalrestat | x-ray diffraction | A | EPR, NAP | 2 (best 0.73) |
| 4JII | Crystal Structure Of AKR1B10 Complexed With NADP+ And Zopolrestat | x-ray diffraction | X | NAP, ZST, NA | 3 (best 0.77) |
| 4JII | Crystal structure of AKR1B10 complexed with NADP+ and zopolrestat | x-ray diffraction | X | NAP, ZST, NA | 3 (best 0.77) |
| 4WEV | Crystal structure of human AKR1B10 complexed with NADP+ and sulindac | x-ray diffraction | X | NAP, SUZ | 1 (best 0.75) |
| 4WEV | Crystal structure of human AKR1B10 complexed with NADP+ and sulindac | x-ray diffraction | X | NAP, SUZ | 1 (best 0.75) |
| 4XZL | Crystal structure of human AKR1B10 complexed with NADP+ and JF0049 | x-ray diffraction | X | NAP, F49 | 2 (best 0.74) |
| 4XZL | Crystal structure of human AKR1B10 complexed with NADP+ and JF0049 | x-ray diffraction | X | NAP, F49 | 2 (best 0.74) |
| 4XZM | Crystal structure of the methylated wild-type AKR1B10 holoenzyme | x-ray diffraction | X | NAP | 2 (best 0.75) |
| 4XZM | Crystal structure of the methylated wild-type AKR1B10 holoenzyme | x-ray diffraction | X | NAP | 2 (best 0.75) |
| 4XZN | Crystal structure of the methylated K125R/V301L AKR1B10 Holoenzyme | x-ray diffraction | X | NAP | 3 (best 0.71) |
| 4XZN | Crystal structure of the methylated K125R/V301L AKR1B10 holoenzyme | x-ray diffraction | X | NAP | 3 (best 0.71) |
| 5LIK | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181 | x-ray diffraction | X | NAP, W8X | 3 (best 0.75) |
| 5LIK | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK181 | x-ray diffraction | X | NAP, W8X | 3 (best 0.75) |
| 5LIU | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388 | x-ray diffraction | X | NAP, 388 | 2 (best 0.74) |
| 5LIU | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor IDD388 | x-ray diffraction | X | NAP, 388 | 2 (best 0.74) |
| 5LIW | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319 | x-ray diffraction | X | NAP, 1WX | 2 (best 0.78) |
| 5LIW | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK319 | x-ray diffraction | X | NAP, 1WX | 2 (best 0.78) |
| 5LIX | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184 | x-ray diffraction | X | NAP, MK4 | 2 (best 0.78) |
| 5LIX | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK184 | x-ray diffraction | X | NAP, MK4 | 2 (best 0.78) |
| 5LIY | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204 | x-ray diffraction | X | NAP, DQP | 2 (best 0.77) |
| 5LIY | Crystal structure of human AKR1B10 complexed with NADP+ and the inhibitor MK204 | x-ray diffraction | X | NAP, DQP | 2 (best 0.77) |
| 5M2F | Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008 | x-ray diffraction | X | NAP, UV8 | 2 (best 0.76) |
| 5M2F | Crystal structure of human AKR1B10 complexed with NADP+ and the synthetic retinoid UVI2008 | x-ray diffraction | X | NAP, UV8 | 2 (best 0.76) |
| 5Y7N | Crystal structure of AKR1B10 in complex with NADP+ and Androst-4-ene-3-beta-6-alpha-diol | x-ray diffraction | A | NAP, 8QL | 1 (best 0.73) |
| 5Y7N | Crystal structure of AKR1B10 in complex with NADP+ and androst-4-ene- 3-beta-6-alpha-diol | x-ray diffraction | A | NAP, 8QL | 1 (best 0.73) |
| O60218 | AlphaFold monomer V2.0 prediction for aldo-keto reductase family 1 member B10 (O60218) | predicted | A | — | — |
Ligands
- NAP · Nadp nicotinamide-adenine-dinucleotide phosphate · in 40 records
- 1WX · {2-[(4-bromo-2,3,5,6-tetrafluorobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid · in 2 records
- 388 · (2-{[(4-bromo-2-fluorobenzyl)amino]carbonyl}-5-chlorophenoxy)acetic acid · in 2 records
- 64I · 2,2',3,3',5,5',6,6'-octafluorobiphenyl-4,4'-diol · in 2 records
- 8QL · (3S,6S,8S,9S,10R,13S,14R)-10,13-dimethyl-2,3,6,7,8,9, 11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6-diol · in 2 records
- CL · Chloride ion · in 2 records
- DQP · {5-chloro-2-[(pentabromobenzyl)carbamoyl]phenoxy}acetic acid · in 2 records
- EPR · {5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl}acetic acid · in 2 records
- F49 · [2,4-dioxo-3-(2,3,4,5-tetrabromo-6-methoxybenzyl)-3,4-dihydropyrimidin-1(2H)-yl]acetic acid · in 2 records
- FID · (2S,4S)-2-aminoformyl-6-fluoro-spiro[chroman-4,4'-imidazolidine]-2',5'-dione · in 2 records
- FLF · 2-[[3-(trifluoromethyl)phenyl]amino] benzoic acid · in 2 records
- MK4 · {5-chloro-2-[(2,4,6-tribromobenzyl) carbamoyl]phenoxy}acetic acid · in 2 records
- NA · Sodium ion · in 2 records
- QAP · 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate · in 2 records
- SBI · Sorbinil · in 2 records
- SUZ · [(1Z)-5-fluoro-2-methyl-1-{4-[methylsulfinyl]benzylidene}-1H-inden-3-yl]acetic acid · in 2 records
- TOL · Tolrestat · in 2 records
- UV8 · 3-bromo-4-[(1E)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-en-1-yl]benzoic acid · in 2 records
- W8X · {2-[(4-bromobenzyl)carbamoyl]-5-chlorophenoxy}acetic acid · in 2 records
- ZST · 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid · in 2 records
Experiment against prediction
- 4GA8 chain A against the predicted model O60218: TM-score 0.99, RMSD 0.80 Å
- 4GA8 chain A against the predicted model O60218: TM-score 0.99, RMSD 0.80 Å
- 4GAB chain A against the predicted model O60218: TM-score 0.99, RMSD 0.79 Å
- 4GAB chain A against the predicted model O60218: TM-score 0.99, RMSD 0.79 Å
- 1ZUA chain X against the predicted model O60218: TM-score 0.99, RMSD 0.81 Å
- 1ZUA chain X against the predicted model O60218: TM-score 0.99, RMSD 0.81 Å
- 4JII chain X against the predicted model O60218: TM-score 0.98, RMSD 0.87 Å
- 4JII chain X against the predicted model O60218: TM-score 0.98, RMSD 0.87 Å
- 4GQG chain A against the predicted model O60218: TM-score 0.98, RMSD 0.86 Å
- 4GQG chain A against the predicted model O60218: TM-score 0.98, RMSD 0.86 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.